# Magnomics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/magnomics-s-a

- Industry: Medical Devices & Equipment
- Headquarters: Cantanhede, Portugal
- Website: www.magnomics.pt
- Total disclosed funding: $1.7M
- Latest round: Seed (Mar 21, 2017)
- Investors on record: 3

## About

Magnomics, S.A. is a biotechnology company focused on developing advanced molecular diagnostics tools for enhanced disease detection and monitoring, particularly in oncology and infectious diseases.Founded in 2013 and headquartered in Cantanhede, Portugal, Magnomics specializes in biotechnology solutions. The company was established by José Germano and has raised a total of EUR 0.25 mn through a SEED funding round in March 2017, with Portugal Ventures as the investor. They have completed 4 deals to date, with the latest occurring on March 21, 2017.Magnomics.pt specializes in biotechnology solutions, focusing primarily on the development and provision of advanced molecular diagnostics tools. Their core product offerings include a suite of diagnostic assays aimed at enhancing disease detection and monitoring, particularly in oncology and infectious diseases. These tools leverage proprietary technology to analyze genetic and biomarker data, helping to facilitate early intervention and personalized treatment plans for patients. The company serves hospitals, laboratories, and research institutions throughout Europe and Asia, contributing to improved healthcare outcomes.Magnomics.pt generates revenue through direct sales of diagnostic products and partnerships with healthcare providers. Their flagship diagnostic assays are offered under tiered pricing plans for individual practitioners and larger institutions. Transactions are structured as B2B sales, enabling clients to purchase products directly or through authorized distributors. Additionally, the company provides ongoing training and support services to ensure effective utilization of their diagnostic tools in clinical settings.Magnomics plans to utilize the recent SEED funding of EUR 0.25 mn to support the development of new diagnostic products aimed at expanding their current offerings. The company is targeting growth in new markets within Southern Europe and Asia by 2025, focusing on regions with high demand for advanced molecular diagnostics. The funding will also facilitate the launch of innovative diagnostic assays in these regions, enhancing their market presence and service delivery.

## Funding rounds

- Seed, Mar 21, 2017, $0.3M — Portugal Ventures
- Seed, Aug 19, 2015, $0.8M — Portugal Ventures
- Seed, May 26, 2014, $0.6M — Portugal Ventures, Beta Capital, Bynd Venture Capital

## Investors

- Portugal Ventures (https://capitalatlas.ai/funds/portugal-ventures) — Seed
- Beta Capital (https://capitalatlas.ai/funds/beta-capital) — Seed
- Bynd Venture Capital (https://capitalatlas.ai/funds/bynd-venture-capital) — Seed